Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox...
By Lisa Pham, Ashleigh Furlong · Bloomberg Markets
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess.